According to the result of IPASS, OPTIMAL, Lux‐lung 3, and 6, the median PFS of EGFR TKI (Gefitinib, Erlotinib, and Afatinib, Dacomitinib and Osimertinib) to the EGFR mutant NSCLC patients was nearly 10–13 months.20, 21, 22, 23 As for ALK arrangement patients, the results of PROFILE 1014, PROFILE 1029 and ALEX study suggest that Crizotinib and Alectinib were sensitive for ALK positive NSCLC patients, and the median PFS was 11–34 months.24, 25 Based on these observations, TKIs may not be suitable for this type of lung cancer. This evidence concerns the gene ALK and lung cancer.